CL CIA

8/7/2019 CL CIA

http://slidepdf.com/reader/full/cl-cia 1/17

.

8/7/2019 CL CIA


` The position when two companies each hold shares in

the other. If such holdings were of significant size this

would make it difficult for either company's

shareholders to displace the existing management; if both were majority holdings it would be impossible to

vote out either set of directors so long as they agreed.

8/7/2019 CL CIA


` In the most simple example of

a cross holding, Company X can hold stocks or bondsissued by Company Y. Company Y's value would be

counted twice if the cross holding was not accounted

for. It would be counted once when looking at the value

of securities issued by the company, and again whenconsidering the securities held by Company X. This

would lead to having skewed information about the

values of companies on the index.

8/7/2019 CL CIA


` The situation in which one publicly-traded

company owns stock in another publicly-traded

company. This situation can lead to double-counting

of securities, especially when the two corporations are

listed on the same index. Thus, one needs to account

for cross holdings when aggregatingthe capitalizations of firms. If two firms cross hold each

other, it is difficult to displace the management in one

without the consent of the other corporation.

8/7/2019 CL CIA


CATEGORY OF

SHAREHOLDER

NO OFSHARE-HOLDERS

TOTALNO

OFSHARES

TOTAL NO OFSHARES HELD IN

DEMATERIALIZEDFORM

TOTALSHAREHOLDING

AS A % OF TOTALNO OF SHARES

AS A % OF(A+B)

AS A % OF

(A+B+C)

SHARESPLEDGED OR

OTHERWISEENCUMBEREDNUMBER OFSHARES

AS A % OF

TOTALNO OFSHARES

(A) Shareholding of Promoter and Promoter Group

(1) Indian

(2) Foreign

Bodies Corporate 1 268,711,323 268,711,323 64 76 63 86 - -

Sub Total 1 268,711,323 268,711,323 64.76 63.86 - -

Totalshareholding of Promoter andPromoter Group

(A)

1 268,711,323 268,711,323 64.76 63.86 - -

8/7/2019 CL CIA


(B) ub c h r ho d ng

( ) n t tut on

Mu u l Fun s / UT 90 12,175,892 12,120,158 2.93 2.89

F n nc l Ins u ns / Banks

54 329,036 291,258 0.08 0.08

Insur anc

Compan s

6 38,361,394 38,361,394 9.25 9.12

For gn Ins u onal Inv s ors

210 32,432,210 32,423,978 7.82 7.71

ub Tot 0 9 5 9 0 0 9 0

8/7/2019 CL CIA


(2) Non-

Institutions

Bodies Corporate 2,294 13,389,893 13,344,575 3.23 3.18

Individuals - - - -

Individualshareholders

holding nominalshare capital up to

Rs. 1 lakh

167,894

44,168,562 37,104,852 10.65 10.50

Individualshareholders

holding nominal

share capital inexcess of Rs. 1lakh

74

5,269,364 5,184,975 1.27 1.25

8/7/2019 CL CIA


Any Others (Specify) 8 81,382 80,742 0.02 0.02 -

Foreign CorporateBodies

8 81,382 80,742 0.02 0.02 -

Sub Total 170,270 62,909,201 55,715,144 15.16 14.95 -

Total Public

shareholding (B)

170,630 146,207,733 138,911,932 35.24 34.75 -

Total (A)+(B) 170,631 414,919,056 407,623,255 100.00 98.61 -

(C) Shares held by

Custodians and against

which Depository

Receipts have been

issued-m

1 5,835,101 5,835,101 - 1.39 -

Total (A)+(B)+(C) 170,632 420,754,157 413,458,356 - 100.00 -

8/7/2019 CL CIA


0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

5

Ca e o y 1 Ca e o y 2 Ca e o y 3 Ca e o y 4

Se ie 1Se ie 2

Se ie 3

8/7/2019 CL CIA


Sa es

1 Qtr 2 d Qtr

3r d Qtr

4th Qtr

8/7/2019 CL CIA


Ranbaxy Laboratories Ltd. M&A Summary

Ranbaxy Laboratories Ltd. has made 16 acquisitions while taking stakes in 13

companies. Ranbaxy Laboratories Ltd. has 6 divestitures during this period.

Year Acquisitions Stakes Divestitures

2009 1 0 0

2008 0 1 2

2007 1 3 0

2006 4 2 0

2005 1 1 0

2004 1 2 1

2003 0 1 12002 3 1 0

2001 0 1 0

2000 1 0 0

1999 0 0 1

1998 0 1 0

1997 2 0 1

1996 1 0 01995 1 0 0

Total 16 13 6

8/7/2019 CL CIA


MD & CEO

8/7/2019 CL CIA


8/7/2019 CL CIA


Mr. Sawhney is a veteran with over three decades of global experience in the Chemical and

Pharmaceutical industries. He has held senior functional and management positions in severalglobal pharmaceutical companies likeMax-Gb, Hindustan Ciba-Geigy, Bayer India Limited andDr. Reddy¶s Laboratories Limited.

Mr. Sawhney is one of the founder members of thePharmaceuticals Export Promotion Council(Pharmexcil) and is currently a member of AdvisoryBoard of USP in India.

An alumnus of IMI, Delhi, he has done hisgraduation in Commerce from Sydenham College of Commerce,Mumbai University.

8/7/2019 CL CIA


Mr. Arun Sawhney, B.Com., PGDBM has been aManaging Director of Ranbaxy Laboratories Ltd.

since August 20, 2010. Mr. Sawhney served asPresident of Bulk SBU andMember of Management Council of Dr. Reddy's LaboratoriesLtd.Mr. Sawhney started his tenure at Dr.Reddy's in 2001, and served as its President -Europe and Global of API business until May5, 2008. Prior to Dr. Reddy's Laboratories's heserved as Chief Executive Officer of Max-GBLtd. Prior to that, Mr. Sawhney Headed the

Global Business Development function atRanbaxy Laboratories Limited.

8/7/2019 CL CIA


Mr. Sawhney has also had successful stints as

Manager Exports with Hindustan Ciba Geigy and as

Regional SalesManager with Bayer India, earlier in

his career.Mr. Sawhney has been a Director of

Ranbaxy Laboratories Ltd. since August 20, 2010. He

serves asMember of the Supervisory Board at

Terapia ,S.A. Mr. Sawhney is a Silver Medalist of

MBA from the InternationalManagement

Institute, New Delhi and has a Bachelors degree in

Commerce from Sydenham College of Commerce

and Economics,Mumbai

8/7/2019 CL CIA


THANK YOU

BY :

ANIRUDH JAIN

IV_BBM

_C0911251

CL CIA

Documents

Transcript of CL CIA